Physician profile
Peter Lim
NPI 1316477995
$6,083.32
in general payments reported to CMS, 2019-2025
40 companies · $2,032 in 2025
The $2,032 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.61 · 2021: $288 · 2022: $953 · 2023: $1,328 · 2024: $1,452 · 2025: $2,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,812.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,041.25 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $932.04 | 2021-2025 | |
| Pfizer INC. | $582.68 | 2021-2025 | |
| Lilly USA, LLC | $444.03 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $402.61 | 2022-2025 | Repatha, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $264.98 | 2021-2025 | Eliquis, Camzyos |
| Otsuka America Pharmaceutical, INC. | $233.40 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $228.11 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lundbeck LLC | $207.84 | 2024-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $203.16 | 2024-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.26 | 2022-2025 | Jardiance |
| Viiv Healthcare Company | $161.82 | 2024-2025 | Apretude |
| Phathom Pharmaceuticals, INC. | $122.38 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $95.06 | 2019-2025 | Farxiga |
| Xeris Pharmaceuticals, INC. | $86.03 | 2024-2025 | Gvoke Hypopen |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.